Showing 2634 results
- https://www.novartis.com/news/media-releases/novartis-data-asco-icml-and-eha-meetings-demonstrate-meaningful-advancements-cancer-careUpdated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be…
- https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-initiative-tackle-hypertension-and-its-root-causes-low-income-urban-communitiesBetter Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension…
- https://www.novartis.com/news/media-releases/novartis-completes-divestment-front-eye-ophthalmology-assetsDivestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic…
- https://www.novartis.com/news/media-releases/sandoz-announces-plans-build-biosimilar-technical-development-center-slovenia-support-future-growth-biosimilar-pipelinePlanned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026New end-to-end drug substance and drug…
- https://www.novartis.com/investors/financial-data/quarterly-results/2023-q2-transcript
- https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-multiple-sclerosis-biosimilar-natalizumabIf approved, will be first-of-a-kind biosimilar natalizumab in Europe, for use in all indications of reference biologic Positive CHMP opinion based on evidence from extensive analytical…
- https://www.novartis.com/careers/early-careers/students
- https://www.novartis.com/careers/early-careers/graduates
- https://www.novartis.com/news/european-commission-ec-adopts-decision-endorsing-chmp-recommendation-revoke-conditional-marketing-authorization-adakveo-crizanlizumab
- https://www.novartis.com/news/media-releases/novartis-presents-data-showing-jakavi-superior-best-available-therapy-patients-less-advanced-polycythemia-vera-pvThree times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1] RESPONSE-2 complements data…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 264
- › Next page